INTRODUCTION: The serum periostin level is a promising biomarker of type 2- high inflammation pattern of bronchial asthma. It has been proven that serum periostin levels decrease in response to systemic and inhaled corticosteroid (ICS) therapy. However, we have only limited knowledge about changes in serum periostin levels reflecting omalizumab (OMA) treatment and other variables, such as chronic rhinosinusitis with nasal polyps (CRSwNP). AIM: To critically appraise clinically relevant parameters influencing periostin levels in asthma patients. MATERIAL AND METHODS: A pilot, cross-sectional, observational study to assess serum periostin levels of 48 asthma patients (38 treated by conventional therapy comprising ICS and 10 treated by ICS and OMA as an add-on therapy) with respect to asthma clinical traits, comorbidities and to other biomarkers of type 2-high asthma phenotype (total IgE, absolute and relative eosinophil count, eosinophilic cationic protein (ECP) and a fraction of exhaled NO (FeNO)). RESULTS: Serum periostin correlates with total IgE levels (Spearman rho = 0.364, p = 0.025) in a subgroup of conventionally treated patients, and with eosinophil count (Spearman rho = 0.401, p = 0.021) in a subgroup of patients with concurrent CRSwNP. Serum periostin levels were decreased in omalizumab-treated patients in comparison to conventionally treated patients (p = 0.025). This effect was remarkably apparent only if CRSwNP was not present (p = 0.005). Conversely, we measured elevated periostin levels in OMA-treated patients with concurrent CRSwNP (p = 0.017). CONCLUSIONS: Serum periostin production is significantly associated with treatment modality (omalizumab vs. conventional) and presence of CRSwNP. These variables need to be taken into account to interpret periostin levels accurately.

Department of Pulmonary Medicine University Hospital in Hradec Králové Faculty of Medicine Charles University Prague Czech Republic

Department of Pulmonary Medicine University Hospital in Pilsen Faculty of Medicine Charles University Prague Czech Republic

Department of Respiratory Diseases Hospital in České Budějovice Faculty of Medicine in Pilsen Charles University Prague Czech Republic

Institute of Clinical Immunology and Allergy University Hospital in Hradec Králové Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Takeshita S, Kikuno R, Tezuka KI, et al. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J. 1993;294:271–8. PubMed PMC

Horiuchi K, Amizuka N, Takeshita S, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999;14:1239–49. PubMed

Conway SJ, Izuhara K, Kudo Y, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci. 2014;71:1279–88. PubMed PMC

Kenji Izuhara A, Conway SJ, Moore BB, et al. Roles of periostin in respiratory disorders. Am J Respir Crit Care Med. 2016;193:949–56. PubMed PMC

Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–95. PubMed PMC

Takayama G, Arima K, Kanaji T, et al. PeriostIn: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118:98–104. PubMed

Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647–54. PubMed PMC

Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Pnas. 2007;104:15858–63. PubMed PMC

Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–98. PubMed

Hanania NA, Wenzel S, Roseń K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–11. PubMed

Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy. 2016;71:1472–9. PubMed

Matsumoto H. Serum periostIn: a novel biomarker for asthma management. Allergol Int. 2014;63:153–60. PubMed

Izuhara K, Ohta SS, Ono J. Using periostin as a biomarker in the treatment of asthma. Allergy Asthma Immunol Res. 2016;8:491–8. PubMed PMC

Hoshino M, Ohtawa J, Akitsu K. Effect of treatment with inhaled corticosteroid on serum periostin levels in asthma. Respirology. 2016;21:297–303. PubMed

Caminati M, Gatti D, Dama A, et al. Serum periostin during omalizumab therapy in asthma: a tool for patient selection and treatment evaluation. Ann Allergy Asthma Immunol. 2017;119:460–2. PubMed

Asano T, Kanemitsu Y, Takemura M, et al. Serum periostin as a biomarker for comorbid chronic rhinosinusitis in patients with asthma. Ann Am Thorac Soc. 2017;14:667–75. PubMed

Ishida A, Ohta N, Suzuki Y, et al. Expression of pendrin periostin in allergic rhinitis chronic rhinosinusitis. Allergol Int. 2012;61:589–95. PubMed

Kou K, Okawa T, Yamaguchi Y, et al. Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis. Br J Dermatol. 2014;171:283–91. PubMed

Terl M, Sedlak V, Cap P, et al. Asthma management: a new phenotype-based approach using presence of eosinophilia and allergy. Allergy. 2017;72:1279–87. PubMed

Katial RK, Bensch GW, Busse WW, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract. 2017;5:S1–14. PubMed

Brusselle GG, Maes T, Bracke KR. Eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19:977–9. PubMed

Godar M, Blanchetot C, de Haard H, et al. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. MAbs. 2018;10:34–45. PubMed PMC

Fingleton J, Braithwaite I, Travers J, et al. Serum periostin in obstructive airways Disease. Eur Respir J. 2016;47:1383–91. PubMed PMC

Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527. PubMed PMC

Arron JR, Izuhara K. Asthma biomarkers: what constitutes a “gold standard”? Thorax. 2015;70:105–7. PubMed

FitzGerald M, Bateman ED, Boulet LP, et al. Global strategy for asthma management and prevention (GINA 2015) 2015. PubMed

Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101:1483–92. PubMed

Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy. J Immunol Methods. 2005;303:81–91. PubMed

Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68. PubMed

Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38. PubMed

Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–15. PubMed PMC

Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations – standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99. PubMed

Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report. Allergy. 2006;61:969–87. PubMed

Fokkens RW, Lund V, Mullol J, et al. EPOS European Position Paper on Rhinosinusitus and Nasal Polyps 2012. Rhinol Suppl. 2012:1–298. PubMed

Melillo G, Balzano G, Bianco S, et al. Report of the INTERASMA working group on standardization of inhalation provocation tests in aspirin-induced asthma: oral and inhalation provocation tests for the diagnosis of aspirin-induced asthma. Allergy. 2001;56:899–911. PubMed

Wagener AH, Yick CY, Brinkman P, et al. Toward composite molecular signatures in the phenotyping of asthma. Ann Am Thorac Soc. 2013;10(Suppl):S197–205. PubMed

Uchida M, Shiraishi H, Ohta S, et al. Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;46:677–86. PubMed PMC

Takahashi K, Meguro K, Kawashima H, et al. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma. 2018;56:236–43. PubMed

Kanemitsu Y, Matsumoto H, Izuhara K, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol. 2013;132:305–12. PubMed

Morra L, Moch H. Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Arch. 2011;459:465–75. PubMed PMC

Shoda T, Futamura K, Kobayashi F, et al. Cell type-dependent effects of corticosteroid on periostin production by primary human tissue cells. Allergy. 2013;68:1467–70. PubMed

Masuoka M, Shiraishi H, Ohta S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122:2590–600. PubMed PMC

Shiraishi H, Masuoka M, Ohta S, et al. Periostin contributes to the pathogenesis of atopic dermatitis by inducing TSLP production from keratinocytes. Allergol Int. 2012;61:563–72. PubMed

Kim MAA, Kyung Yoon M, Lee YSS, et al. Clinical implication of the serum periostin level for differentiating phenotypes of NSAID hypersensitivity. Allergol Int. 2016;65:492–4. PubMed

Kimura H, Konno S, Makita H, et al. Serum periostin is associated with body mass index and allergic rhinitis in healthy and asthmatic subjects. Allergol Int. 2018;67:357–63. PubMed

Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110–6.e1. PubMed